TRDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Entrada Therapeutics Inc (TRDA) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 to invest. Despite bullish technical indicators and positive analyst ratings, the company's weak financial performance, insider selling, and lack of significant trading trends suggest caution. The stock may have potential in the long term, but current risks outweigh the benefits for this investor profile.
The technical indicators are bullish with a positive MACD histogram (0.138), RSI_6 at 86.751 indicating overbought conditions, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels with resistance at R1: 12.503 and R2: 13.069.
Positive analyst ratings with a Buy rating and price targets of $20-$21, indicating significant upside potential.
The company's focus on the $1.4 billion Duchenne Muscular Dystrophy market and 'catalyst-rich' pipeline.
Participation in the J.P. Morgan Healthcare Conference to seek partnerships and investor support.
Insider selling has increased by 374.09% over the last month.
Weak financial performance in Q4 2025, with revenue down 96.53% YoY and net income down 3481.08% YoY.
Revenue significantly missed expectations in the latest quarter.
No significant trading trends from hedge funds.
The company's Q4 2025 financials showed a significant decline in revenue (-96.53% YoY), net income (-3481.08% YoY), and EPS (-3166.67% YoY). Gross margin dropped to 0, indicating no profitability. However, the company has $296 million in cash, providing a runway into Q3 2027.
Analysts are bullish on TRDA, with Buy and Outperform ratings and price targets of $20-$21. They highlight the company's undervaluation, strong pipeline, and potential for significant upside by 2026.
